A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas

Leukemia and Lymphoma

Volumn 51, Issue 3, 2010, Pages 447-455

  Weidmann, Eckhart ^a   Hess, Georg ^b   Chow, Kai U ^c   Krause, Stefan W ^d   Subklewe, Marion ^e   Kruse, Judith ^a   Weisel, Katja C ^f   Soekler, Martin ^f   Kim, Soo Zin ^g   Napieralski, Simone ^h   Rech, Jürgen ⁱ   Dreyling, Martin ^j   Jäger, Elke ^a   Mitrou, Paris S ^g  

^a KRANKENHAUS NORDWEST   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c Medical Center   (Germany)

^d UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY OF TÜBINGEN   (Germany)

^g GOETHE UNIVERSITY   (Germany)

^h PHILIPPS UNIVERSITY MARBURG   (Germany)

ⁱ UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^j LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

more..

Author keywords

Alemtuzumab; Fludarabine; Peripheral T cell lymphoma (PTCL)

Indexed keywords

ALEMTUZUMAB; CLEMASTINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FAMCICLOVIR; FLUDARABINE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; PARACETAMOL; PREDNISONE; SEROTONIN ANTAGONIST; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; MONOCLONAL ANTIBODY; VIDARABINE;

ADULT; AGED; ANEMIA; ARTICLE; BRAIN HEMORRHAGE; BRONCHOSPASM; CARDIOTOXICITY; CHILL; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEART FAILURE; HUMAN; INFECTION; LEUKOPENIA; LUNG TOXICITY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RELAPSE; SKIN MANIFESTATION; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUBERCULOSIS; VIRUS INFECTION; ANALOGS AND DERIVATIVES; DISEASE FREE SURVIVAL; LYMPHOMA, T-CELL; MIDDLE AGED; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME; VIDARABINE;

EID: 77249113760     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903580402     Document Type: Article

References (26)

1. Weidmann E, Gramatzki M, Wilhelm M, Mitrou PS. Diagnosis and actual therapy strategies in peripheral T-cell lymphomas: summary of an international meeting. Ann Oncol 2004;15:369-374.
2. Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004; 103:2474-2479.
3. Greer JP. Therapy of peripheral T/NK neoplasms. Hematol Am Soc Hematol Educ Program 2006:331-337.
4. Salisbury JR, Rapson NT, Codd JD, Rogers MV, Nethersell AB. Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas. J Clin Pathol 1994; 47:313-317.
5. Gilleece MH, Dexter TM. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 2006;82: 807-812.
6. Ginaldi L, De Martinis M, Matutes E, et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998;22:185-191.
7. Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004;103:2920-2924.
8. Zinzani PL, Alinari L, Tani M, Fina M, Pileri S, Baccarani M. Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica 2005;90:702-703. (Pubitemid 40780898)
9. Dearden CE, Matutes E, Cazin B, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 2001;98:1721-1726.
10. Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003;101:4267-4272.
11. Gallamini A, Zaja F, Patti C, et al. Alemtuzumab (Campath- 1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007;110:2316-2323.
12. Kim JG, Sohn SK, Chae YS, et al. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol 2007;60:129-134.
13. Intragumtornchai T, Bunworasate U, Nakorn TN, Rojnuckarin P. Alemtuzumab in combination with CHOP and ESHAP as first-line treatment in peripheral T-cell lymphoma. Blood 2006;108(Suppl. 1):286b (Abstract 4740).
14. Ravandi-Kashani F, Kantarjian H, Faderl S, et al. Combination therapy with alemtuzumab and pentostatin is effective and has acceptable toxicity in patients with T-lymphoid neoplasms. Blood 2006;108(Suppl. 1):330b (Abstract 4971).
15. Scarisbrick JJ, Child FJ, Clift A, et al. A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma. Br J Dermatol 2001;144:1010-1015.
16. Yamaguchi M, Kotani T, Nakamura Y, Ueda M. Successful treatment of refractory peripheral T-cell lymphoma with a combination of fludarabine and cyclophosphamide. Int J Hematol 2006;83:450-453.
17. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
18. Keating M, Coutré S, Rai K, et al. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma 2004;4:220-227. (Pubitemid 38528876)
19. O'Brien SM, Keating MJ, Mocarski ES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma 2006;7:125-130.
20. Osterborg A, Karlsson C, Lundin J, Kimby E, Mellstedt H. Strategies in the management of alemtuzumab-related side effects. Semin Oncol 2006;33(Suppl. 5):S29-S35.
21. Elter T, Borchmann P, Schulz H, et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005; 23:7024-7031.
22. Lin TS, Donohue KA, Lucas MS, et al. Consolidation therapy with subcutaneous (sc) alemtuzumab results in severe infectious toxicity in previously untreated CLL patients who achieve a complete response (CR) after fludarabine and rituximab (FR) induction therapy: interim safety analysis of the CALGB study 10101. Blood 2007;110(Suppl. 1):216a (Abstract 755).
23. O'Brien SM, Kantarijan HM, Thomas DA, et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003;98: 2657-2663.
24. Kluin-Nelemans HC, Coenen JL, Boers JE, van Imhoff GW, Rosati S. EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Blood 2008;112:1039-1041.
25. Lenihan DJ, Alencar AJ, Yang D, Kurzrock R, Keating MJ, Duvic M. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. Blood 2004;104:655-658.
26. Lundin J, Kennedy B, Dearden C, Dyer MJ, Osterborg A. No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome. Blood 2005;105:4148-4149.